Pharmacovigilance Case Management Software Problems: The 7 That Break the Clock, and How to Avoid Them

Why does a safety build turn into a full quality management system?

The problem that justifies the project is usually narrow and correct: intake is the bottleneck, not medical assessment. Cases arrive from six channels, triage is manual, and duplicate handling eats hours the clock does not have.

Then the scope grows in a very particular direction. If we are building a validated system anyway, should it hold deviations. Should it manage change control. Should regulatory affairs use it for submissions. Should quality use it for corrective actions. Each addition is defensible, and each one drags in another set of stakeholders, another validation surface and another approval cycle. A twenty week release becomes a two year programme, and the safety team is still working the same backlog.

The reason this hurts more here than in most industries is validation. Every extra module is not just development, it is user requirements, specifications, test protocols, execution and approved evidence, and validation typically adds twenty to thirty percent on top of build cost. Scope growth in a validated environment compounds rather than adds.

The discipline that works is to scope the first release around the clock. Intake from your real channels, triage, case processing, Medical Dictionary for Regulatory Activities (MedDRA) coding and E2B(R3) generation. Nothing that does not touch a reporting obligation. In Digital Heroes delivery experience that release runs $180,000 to $400,000 and ships in 20 to 28 weeks. The full platform, adding partner data exchange, literature screening, aggregate reporting and signal management, runs $450,000 to $1,200,000 phased over 14 to 24 months. Quality management belongs in a separate system with a separate validation, and every safety department that merged the two regretted the release cycle.

What goes wrong migrating legacy cases, versions and submission history?

Safety migration is heavier than it looks because you are migrating history, not current state, and the history is what an inspector asks about.

A case is a versioned object. Version three amended version two after follow up arrived, seriousness was reassessed, expectedness was evaluated against a specific version of the reference safety information, and each version produced its own submissions to different authorities on different dates with different acknowledgements. Migrate only the latest state and you have destroyed the ability to answer why a case was upgraded in March, which is a question that gets asked.

Coded terms are the second trap. Terms were coded under the MedDRA version in force at the time, and dictionary upgrades change term hierarchies. A migration that recodes everything to the current version silently rewrites history. A migration that carries the original coded terms without recording which version produced them makes the data uninterpretable later. Both happen.

The third is the submission ledger. If your legacy system recorded submissions as a status flag rather than as dated events with acknowledgements, that history cannot be reconstructed and you need to say so explicitly rather than fabricate it.

The pragmatic approach that survives inspection is to migrate open and recently closed cases in full, including versions, coded terms with their dictionary version and the complete submission ledger, migrate older cases in a reduced and clearly labelled form, and keep the legacy system available read only for a defined period with that decision documented and approved. Write down what was not migrated and why. An inspector will accept a reasoned, documented scope decision far more readily than a gap discovered during questioning.

Why do the gateway, dictionary and partner E2B integrations break after launch?

Three integration surfaces dominate this category and each fails in its own way.

Gateway submission fails on acknowledgements rather than on transmission. A message goes out, and what comes back may be a positive acknowledgement, a negative acknowledgement with a validation error, or nothing at all within the expected window. The failure mode that hurts is silence: a submission recorded as sent, no acknowledgement received, and nobody watching the gap. Every submission needs an expected acknowledgement window, an alarm when it passes, and a resolution workflow for negative acknowledgements that ends in a resubmission with its own ledger entry.

Dictionary upgrades break coding. MedDRA and drug dictionaries are versioned and updated on a schedule, and an upgrade changes term relationships. If your system codes against whatever version is loaded rather than recording the version used, you cannot explain historical coding decisions. Upgrades also need an impact assessment run before they are applied, because terms that changed status affect open cases and aggregate outputs.

Partner exchange is the messiest and the least standardised. Each safety data exchange agreement is a bespoke set of obligations, formats, timelines and reconciliation frequencies negotiated in a contract that lives with the legal team, not in a standard. Partners send files with their own quirks, and a partner who changes their export without telling you produces a batch that fails validation on a Friday. Build partner obligations as configuration with a named owner per agreement, validate incoming batches with a clear rejection path back to the partner, and reconcile counts on the agreed cadence rather than at year end.

What happens when validation and audit trail obligations are not covered?

This is where a technically capable build becomes unusable in a regulated environment.

Computer system validation is a genuine workstream, not documentation written at the end. It is user requirements traceable to specifications, traceable to test cases, traceable to executed and approved evidence, with defined roles and approvals. Building the system first and validating afterwards produces a retrospective exercise that costs more, takes longer and satisfies nobody.

The audit trail obligations under 21 CFR Part 11 and equivalent expectations elsewhere are specific and structural. Records are attributable, legible, contemporaneous, original and accurate. Nothing is deleted. Changes are recorded with who, when, what and why. Electronic signatures are bound to the records they sign. These are data model decisions made in week one, not features added in month eight.

The obligation people most often miss is change control after go live. A safety system changes constantly, because products get added, markets get added, reference safety information gets updated and partner agreements get signed. A validation approach that assumes a frozen system will strangle you within a year, at which point staff start working around the system, which is the outcome the validation existed to prevent. Ask any developer how a new product gets added six months after go live and how much of the validation package that touches. If the answer is a full revalidation, the design is wrong.

Should you build custom or configure the safety system you already have?

For a large number of companies the honest answer is buy or outsource, and we say so regularly.

If you have one product in one region and a modest case volume, licence Ennov Safety or another mid market system, or outsource case processing to a service provider. It will cost far less than a build, get you compliant faster, and let your attention stay on the science. Building a validated safety system to handle a few hundred cases a year is a poor use of capital and of your qualified person's time.

Oracle Argus Safety, ArisGlobal LifeSphere Safety and Veeva Vault Safety are all comprehensive and none of them fails at core case processing. If you already run one and your pain is that intake is manual and configuration changes take months, look hard at whether the pain is the product or the operating model around it. Vendor and consultant queues, internal change control and a validation cycle that treats every configuration as a project are frequently the real constraint, and no replacement fixes an operating model.

Where configuration genuinely runs out is at the edges the product cannot see. Intake from your specific channels. Reconciliation against partner agreements that exist only in contracts. An obligation engine that computes clocks from your product, market and agreement combinations. Cost that scales with headcount rather than case volume. When two or more of those are true and the licence and change cost curve has stopped matching the size of the problem, a build starts to earn its place.

How do hidden costs get into the quote?

Four cost drivers dominate here and the first is usually the only one quoted.

Markets and gateways, because each has its own submission behaviour, acknowledgement handling and local requirements, and adding the third is not a third of the effort of the first. Partner agreements, each a bespoke rules set. Dictionary licensing and version management, which is a recurring cost and an operational process rather than a one off. And validation, which typically adds twenty to thirty percent and should appear as its own line.

Then the ones that surface later. Gateway connectivity testing involves a third party and does not compress, so it is a schedule risk as well as a cost. Legacy migration of versions and submission history, which is heavier than a data load. Your own team's time on user requirements, test execution and approvals, which is substantial in a validated project and cannot be delegated to the developer. And the ongoing cost of change control after go live, which is the line that determines whether the system stays useful in year three.

Ask for the quote split into build, validation and migration, with assumptions and exclusions stated. A developer who cannot separate those three has not delivered a validated system.

What separates a build that works from one that fails here?

Ask one question first: what happens to a case when follow up information arrives after submission. A credible answer covers versioning, reassessment of seriousness and expectedness against the correct reference safety information version, recomputation of obligations across every market and partner agreement, and a new submission with its own ledger entry. An answer about updating the record describes a database, not a safety system, and everything downstream of that misunderstanding will be wrong.

Ask how automated extraction is made auditable. The right answer preserves the source text, records what was suggested, records what the reviewer confirmed or changed, and never lets a model make a reportability or seriousness determination on its own. Language models genuinely earn their place in two narrow jobs here, turning an unstructured narrative into candidate structured fields for verification, and ranking literature abstracts by likelihood of containing a reportable case. Both keep a human decision point. A build that hides an automated decision inside a model will not survive an inspection and should not.

Ask how duplicate detection works. Rule based matching on name, date of birth and event date misses obvious duplicates and flags obvious non duplicates, because a physician report and a spouse report of the same event differ in dates, symptoms and identifiers. Surfacing semantically similar narratives for a human decision is the workable approach, and the decision plus its rationale has to be recorded.

The builds that succeed run validation alongside development rather than after it, and involve the safety team in design reviews rather than showing them a finished product. The builds that fail are designed around an idealised case flow that the department has never actually experienced.

Settle ownership before kickoff. You should own the repository, the infrastructure accounts and the complete validation package. That matters particularly here, because the qualified person responsible for pharmacovigilance is personally accountable for a system they must be able to change.